Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Keerthi K
Eligibility
Inclusion criteria
Inclusion criteria: Prospective Group: 1.Treatment naïve biopsy proven breast cancer patients. 2.Patients with benign breast diseases (with a breast lump) willing to participate in the study 3.Individuals from the general population, >= 18 years of age willing to participate would be taken as controls Retrospective Group: Breast cancer patients who have been enrolled in previous study (vide ethical clearance number IECPG- 572/20, CTRI registration not done for that study)
Exclusion criteria
Exclusion criteria: 1.Patients with metastatic breast cancer 2.Patients not willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To study the expression of gamma synuclein in the serum and the breast cancerous tissue in patients with breast cancer. 2. To study the expression of serum gamma synuclein in breast cancer, benign breast disease and controls Timepoint: The levels of gamma synuclein will be measured 1)at time of first outpatient visit,2) tissue taken for biopsy 3) before starting neoadjuvant chemotherapy 4) after 3 cycles of chemotherapy 5) tissue taken at the time of surgery 6) 2 weeks after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To study the differential expression of gamma synuclein in breast cancer tissue, adjacent non-cancerous breast tissue and benign breast tumours. 2.To study the impact of gamma synuclein on oncological outcome of patients undergoing treatment for breast cancer and assess its correlation with the known quantitative prognostic markers. Timepoint: The outcomes of locoregional recurrence, morbidity and mortality will be assessed at follow up of patients at time of follow up visit at 3 months interval during the first year, followed by 6 monthly intervals during second and third years then yearly follow up. those unable to attend in person will be followed up through telephonic conversations | — |
Countries
India
Contacts
Public ContactKeerthi K
All India Institute of Medical Sciences,New Delhi
Outcome results
None listed